Notes to the pathophysiology of myelodysplastic syndrome, demethylation therapy and the role of cytokine-induced differentiation
Abstract
Myelodysplastic syndrome (MDS ) is a serious cancer blood disease , which is insufficient production of blood cells and the gradual transition in acute myeloid leukemia (AML) . treatment of MDS upper middle and high-risk transformation to AML is a dangerous disease which survival is highly dependent on whether or not treatment with 5 - azacytidine (AZA ) . in two years after the start of treatment in the Czech Republic and the world allows AZA survival of about half of the patients compared to one fifth of the survivors supportive care. In addition , AZA allows for a certain degree of cure from a minimum response to achieve complete remission.
Despite significant achievements is the effect of AZA time bounded , not all patients respond to AZA at stopping the disease returns and subsequently loses Answer the AZA. All these dark pages in the field MDS makes us more study pathophysiological context MDS and especially arouses motivation attempt of identifying the substances potentiating effect of AZA .